You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

199 Results
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Apr 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Updated
Jul 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma
New Drug Funding Program
    Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma
New Drug Funding Program
    Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Drug
Other Name(s): Columvi®
Jan 2025
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Tecvayli®
Jan 2025
Drug
Other Name(s): Keytruda®
Jun 2025
Drug
Other Name(s): Cabometyx®
May 2025

Pages